A breakthrough in the collagen space, Rousselot presents Nextida GC® , a specific collagen peptide composition developed to deliver targeted metabolic health.
Nextida GC has been shown to naturally stimulate GLP-1 release and support glucose control—providing health benefits that go beyond collagen’s traditional structural roles (Grasset et al. 2024).
With its unique mechanism and science-backed results, Nextida GC starts a new chapter for manufacturers in the functional health and nutrition markets.
GLP-1: putting the brakes on the glucose rollercoaster
The incretin effect: the link between GLP-1, GIP and glucose control
Figure 1: GIP and GLP-1 are secreted by cells located in the intestine. Their combined function is key to maintaining healthy glucose levels after a meal.
A targeted bioactive collagen peptide composition
The ideal candidate to enhance GLP-1 effect
Murine STC-1 cells incubated for 2 hours with in vitro digested collagen peptide compositions at 10 mg.mL-1 (w/v) Grasset E, et al, 2024. https://doi.org/10.1002/fsn3.4538
Nextida GC was the best performing collagen peptide composition to enhance GLP-1 secretion in vitro
Figure 2: In vitro screening of a proprietary library of specific collagen peptide compositions for their ability to enhance natural GLP-1 secretion in murine, gastrointestinal enteroendocrine, STC-1 cells. All screened peptide compositions first underwent an in vitro digestive process to mimic human gastrointestinal digestion and maximize the bioavailability of the peptides.
Nextida GC: clinical evidence
Key Findings
Nextida GC enhanced endogenous GLP-1 and GIP release
Nextida GC significantly lowered the post-meal glucose spikes
Nextida GC supported a balanced insulin response
Key Findings
Nextida GC increased GLP-1 response to lower glucose spikes by 37%, without insulin overstimulation
Figure 3: Schematic illustration of the clinical trials protocol.
*Rousselot data 2026, manuscript under preparation.
New Findings
GLP-1 remained significantly higher than the control in the 2 h after a carbohydrate-rich meal
Nextida GC slowed gastric emptying by over 37 minutes in prediabetic subjects
Nextida GC-induced priming of GLP-1 secretion linked to attenuated post-meal glucose spikes
Figure 3: Schematic illustration of the clinical trials protocol.
Nextida GC: confirmation study findings
Nextida GC significantly boosted GLP-1 production
Nextida GC intake significantly increased GLP-1 secretion by approximately 52.8% vs placebo in vitro
Figure 4: Oral intake of 10-grams Nextida GC significantly increased GLP-1 levels in the blood of a healthy heterogeneous population (normoglycemic and with imbalanced glucose metabolism, i.e. prediabetic). *** p < 0.0001.
Nextida GC significantly enhanced and prolonged GLP-1 levels after meal
Nextida GC significantly increased GLP-1 levels by 82% vs placebo and led to higher GLP-1 levels up to 2 hrs post-meal
Figure 5: Oral intake of 10-grams Nextida GC significantly increased GLP-1 levels in the blood of a healthy heterogeneous population (normoglycemic and with imbalanced glucose metabolism, i.e. prediabetic) and maintained higher GLP-1 levels at all time points up to 2 h after the meal.
* p < 0.05, ** p < 0.001.
Nextida GC boosted GIP production
Nextida GC intake significantly increased GIP secretion by 70% vs placebo, potentially acting in synergy with other hormones such as GLP-1
Figure 6: Oral intake of 10-grams Nextida GC significantly increased GIP release in the blood of a healthy heterogeneous population (normoglycemic and with imbalanced glucose metabolism, i.e. prediabetic). *** p < 0.0001.
Nextida GC reduced post-meal glucose spikes
Nextida GC intake 30 minutes before a mixed meal significantly reduced post-meal glucose by 37% vs placebo
Figure 7: Oral intake of 10-grams Nextida GC significantly reduced the post-meal glucose spike in a healthy heterogeneous population (normoglycemic and with imbalanced glucose metabolism, i.e. prediabetic).
* p < 0.05, *** p < 0.0001.
Nextida GC improved insulin response through pre-meal priming
Nextida GC intake increased insulin secretion before the meal (priming effect), resulting in a significantly lower post-meal insulin response vs placebo
These findings indicate that oral supplementation with Nextida GC prepared the body to receive food by implementing a priming effect, where the body is readied for an incoming meal. This allowed the body to react more efficiently, lowering the post-meal spike without the need for further insulin production
Figure 8: A) Before the mixed meal, oral intake of 10-grams Nextida GC led to a small but significant increase in insulin production in a healthy heterogeneous population (normoglycemic and with imbalanced glucose metabolism, i.e. prediabetic). B) Post-meal, the insulin levels of normoglycemic and prediabetic individuals that took Nextida GC 30 min before the mixed meal were significantly lower than those of individuals that took the placebo.
*** p < 0.0001.
Nextida GC significantly slowed gastric emptying
Nextida GC intake significantly slowed down gastric emptying by 37.2 min vs placebo
Figure 9: Oral intake of 10-grams Nextida GC significantly slowed down gastric emptying in a population with imbalanced glucose metabolism (prediabetic).
* p < 0.05.
A clinically studied ingredient for metabolic health:
As such, Nextida GC's specific collagen peptide composition could deliver multi-benefit support—from satiety and weight management to mood and stress response—through improved glycaemic control and reduced post-meal glucose spikes.
Ask our experts for more information.
Disclaimer
Rousselot makes no representation or warranty, whether expressed or implied, as to the accuracy, reliability, or completeness of the information, nor does it assume any legal liability, whether direct or indirect, for any information. Use of this information shall be at your discretion and risk. Nothing herein relieves you from carrying out your own suitability determinations and tests and from your obligation to comply with all applicable laws and regulations and to observe all third party rights. This product is not intended to diagnose, treat, cure, or prevent any disease.